Genetics of PLCG2 expression and splicing relative to Alzheimer's disease risk.

Andrew K Turner, Kennedy Dotson, Qi Qiao, Kailey Cain, James F Simpson, David W Fardo, Steven Estus
{"title":"Genetics of <i>PLCG2</i> expression and splicing relative to Alzheimer's disease risk.","authors":"Andrew K Turner, Kennedy Dotson, Qi Qiao, Kailey Cain, James F Simpson, David W Fardo, Steven Estus","doi":"10.21203/rs.3.rs-6735123/v1","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>PLCG2 is associated with the risk of Alzheimer's disease (AD) through a rare missense polymorphism, rs72824905 (P522R) as well as a common variant, rs12445675, within a long non-coding RNA adjacent to <i>PLCG2</i>. Elucidating the impact of genetics on PLCG2 expression and splicing will provide insights into the role of PLCG2 in AD risk and, potentially, treatments that might reduce AD risk.</p><p><strong>Objective: </strong>To evaluate <i>PLCG2</i> expression and splicing as a function of AD genetics.</p><p><strong>Methods: </strong><i>PLCG2</i> isoform expression was detected by PCR and quantified by qPCR in AD and non-AD brain samples and in blood buffy coat samples. The function of a genetic variant, rs107164, was tested by using a minigene approach with both alleles in murine BV-2 microglial cells. The impact of ectopic splicing factor expression on PLCG2 minigene splicing was also tested in BV-2 cells. The extent that endogenous levels of a novel <i>PLCG2</i> mRNA isoform lacking 65 bp within exon 28 (D65-PLCG2) were affected by nonsense mediated decay (NMD) was determined by using cycloheximide <i>in vitro</i>. Lastly, whether <i>D65-PLCG2</i> manifested a Ca + 2 response similar to <i>PLCG2</i> was tested by comparing D65-PLCG2-GFP and PLCG2-GFP fusion proteins in transfected HEK293 cells.</p><p><strong>Results: </strong>We report <i>PLCG2</i> isoforms that include (i) a transcript that replaces <i>PLCG2</i> exon 1 with sequence from an adjacent long noncoding (LNC) RNA (<i>LNC-PLCG2</i>) and (ii) a transcript that lacks 65 bp from the beginning of exon 28 (<i>D65-PLCG2</i>). The ratio of <i>LNC-PLCG2</i> to canonical <i>PLCG2</i> was associated with rs12445675 genotype in both human brain and buffy coat samples. The proportion of <i>PLCG2</i> expressed as <i>D65-PLCG2</i> was increased by the T allele of rs1071644, a T/C SNP within the 65bp variably spliced portion of exon 28. This SNP was demonstrated to be functional in a minigene splicing assay. Moreover, the rs1071644-T allele was found to be associated with increased AD risk, independent of rs72824905 (P522R) and rs12445675. <i>D65-PLCG2</i> was susceptible to nonsense mediated RNA decay. D65-PLCG2 was not responsive to Ca<sup>+ 2</sup> in a fashion similar to that observed for PLCG2. Hence, the rs1071644-T allele appears to increase AD risk by increasing the proportion of <i>PLCG2</i> expressed as <i>D65-PLCG2</i>, representing a loss of PLCG2 function.</p><p><strong>Conclusions: </strong>We report that two AD genetic risk factors, rs12445675 and rs1071644, affect AD risk by impacting the <i>LNC-PLCG2</i> to <i>PLCG2</i> ratio and <i>PLCG2</i> exon 28 splicing, respectively.</p>","PeriodicalId":519972,"journal":{"name":"Research square","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12204370/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Research square","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21203/rs.3.rs-6735123/v1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: PLCG2 is associated with the risk of Alzheimer's disease (AD) through a rare missense polymorphism, rs72824905 (P522R) as well as a common variant, rs12445675, within a long non-coding RNA adjacent to PLCG2. Elucidating the impact of genetics on PLCG2 expression and splicing will provide insights into the role of PLCG2 in AD risk and, potentially, treatments that might reduce AD risk.

Objective: To evaluate PLCG2 expression and splicing as a function of AD genetics.

Methods: PLCG2 isoform expression was detected by PCR and quantified by qPCR in AD and non-AD brain samples and in blood buffy coat samples. The function of a genetic variant, rs107164, was tested by using a minigene approach with both alleles in murine BV-2 microglial cells. The impact of ectopic splicing factor expression on PLCG2 minigene splicing was also tested in BV-2 cells. The extent that endogenous levels of a novel PLCG2 mRNA isoform lacking 65 bp within exon 28 (D65-PLCG2) were affected by nonsense mediated decay (NMD) was determined by using cycloheximide in vitro. Lastly, whether D65-PLCG2 manifested a Ca + 2 response similar to PLCG2 was tested by comparing D65-PLCG2-GFP and PLCG2-GFP fusion proteins in transfected HEK293 cells.

Results: We report PLCG2 isoforms that include (i) a transcript that replaces PLCG2 exon 1 with sequence from an adjacent long noncoding (LNC) RNA (LNC-PLCG2) and (ii) a transcript that lacks 65 bp from the beginning of exon 28 (D65-PLCG2). The ratio of LNC-PLCG2 to canonical PLCG2 was associated with rs12445675 genotype in both human brain and buffy coat samples. The proportion of PLCG2 expressed as D65-PLCG2 was increased by the T allele of rs1071644, a T/C SNP within the 65bp variably spliced portion of exon 28. This SNP was demonstrated to be functional in a minigene splicing assay. Moreover, the rs1071644-T allele was found to be associated with increased AD risk, independent of rs72824905 (P522R) and rs12445675. D65-PLCG2 was susceptible to nonsense mediated RNA decay. D65-PLCG2 was not responsive to Ca+ 2 in a fashion similar to that observed for PLCG2. Hence, the rs1071644-T allele appears to increase AD risk by increasing the proportion of PLCG2 expressed as D65-PLCG2, representing a loss of PLCG2 function.

Conclusions: We report that two AD genetic risk factors, rs12445675 and rs1071644, affect AD risk by impacting the LNC-PLCG2 to PLCG2 ratio and PLCG2 exon 28 splicing, respectively.

PLCG2表达和剪接与阿尔茨海默病风险的遗传学关系
PLCG2通过一种罕见的错义多态性rs72824905 (P522R)以及与PLCG2相邻的长链非编码RNA中的一种常见变异rs12445675与阿尔茨海默病(AD)的风险相关。阐明基因对PLCG2表达和剪接的影响将有助于了解PLCG2在AD风险中的作用,并有可能降低AD风险的治疗方法。目的探讨PLCG2的表达和剪接在AD遗传中的作用。方法采用PCR检测PLCG2异构体在AD、非AD脑组织和血灰白色被标本中的表达,并采用qPCR定量。在小鼠BV-2小胶质细胞中,使用带有两个等位基因的minigene方法检测了遗传变异rs107164的功能。我们还在BV-2细胞中检测了异位剪接因子表达对PLCG2迷你基因剪接的影响。体外环己亚胺测定了28外显子缺失65 bp的PLCG2 mRNA内源性异构体(D65-PLCG2)水平受无义介导的衰变(NMD)的影响程度。最后,通过比较转染HEK293细胞中的D65-PLCG2- gfp和PLCG2- gfp融合蛋白,检测D65-PLCG2是否表现出与PLCG2相似的Ca + 2反应。我们报道的PLCG2亚型包括(i)一个转录物用邻近的长非编码(LNC) RNA序列替换PLCG2外显子1 (LNC -PLCG2)和(ii)一个转录物从28外显子开始缺少65bp (D65-PLCG2)。LNC-PLCG2与典型PLCG2的比值与rs12445675基因型相关。rs1071644的T等位基因增加了PLCG2表达为D65-PLCG2的比例,rs1071644是28外显子65bp可变剪接部分的T/C SNP。该SNP在迷你基因剪接实验中被证明是功能性的。此外,发现rs1071644-T等位基因与AD风险增加相关,独立于rs72824905 (P522R)和rs12445675。D65-PLCG2对无义介导的RNA衰变敏感。D65-PLCG2对Ca + 2没有反应,与PLCG2相似。因此,rs1071644-T等位基因似乎通过增加PLCG2表达为D65-PLCG2的比例来增加AD风险,代表PLCG2功能的丧失。我们报道了两个AD遗传危险因素rs12445675和rs1071644分别通过影响LNC-PLCG2与PLCG2的比例和PLCG2外显子28剪接来影响AD的风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信